Carcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
|
|
- Myles Hines
- 6 years ago
- Views:
Transcription
1 Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona
2 National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% SCC 35% 28% 26% 27% Non SCC 65% 72% 75% 72% An oncology outcomes database administered by the American College of Surgeons and the American Cancer Society M. Behera WCLC 2015
3 NSCLC Classification
4 X40 Courtesy of J.C. Soria
5 178 resected lung SqCC Squamous NSCLC has a high somatic mutation burden and complex tumor genetic alterations The Cancer Genome Atlas (TCGA) initiative Imielinski, TCGA, Nature 2012
6 TCGA : Focal copy number alterations in SCC Amplifications Deletions MYCL MCL1 NFE2L2 REL SOX2 PDGFRA LRP1B ERBB4 FOXP1 EGFR FGFR1 CSMD1 CDKN2A MDM2 ERBB2 CCND1 RB1 PTEN CRKL The Cancer Genome Atlas (TCGA) initiative Imielinski, TCGA, Nature 2012
7 PI3K and FGFR1 the 2 main pathways? Comprehensive genomic profiling of 79 stage IV SQCLCs 2 major SqCLC subtypes: FGFR1 amplified and PI3K aberrant. PI3K-aberrant tumors had worse survival and more brain mets Cancer Discovery, April 30, 2015 MINI13.05: Marc Ladanyi Discussant Paik P et al, Cancer Discovery 2015
8 Most common Driver mutations in lung cancer Adenocarcinoma Squamous cell Gene Lung ADC Lung Squamous Cell EGFR 14%, most at known sites Amplification (7%), rare non-canonical mutation (L861Q) KRAS 31% mutation 1%, HRAS more common BRAF 10%, 2% (V600/601) 4%, (no V600/601) PIK3CA 7% mutation 16% mutation ERBB2 5% mutation 3% non-canonical, rare amplification (<5%) FGFRs 2% mutation 10% amplification, 12% mutation, fusions DDRs 3% mutation 4% mutation Mountain, Chest 1997 Lung Cancer Consortium, ASCO 2011; Perez-Moreno et al. Clin Cancer Res 2012; Y. Shi, WCLC 2015
9 Overall survival % Overall survival Overall survival First line Chemotherapy Pacli + carbo (PCb) Cis + vin (CV) Pacli + cis (PC) Gem + cis (GC) Doc + cis (DC) Pacli + carbo (PCb) Pacli + carbo (PCb) Gem + cis (GC) Cis + vin (CV) Months Months Months 30 Study arm OS (mo) 1 year (%) PCb CV Study arm OS (mo) 1 year (%) PC GC DC PCb Study arm OS (mo) 1 year (%) PCb GC CV Kelly et al. J Clin Oncol 2001 Schiller et al. N Engl J Med 2002 Scagliotti, et al. J Clin Oncol 2002 N. Thatcher ELCC 2015
10 New chemo standards?... Probably not Nab-Paclitaxel Nab-Paclitax. Carboplatin Paclitaxel CBDCA Docetaxel Nedaplatin WJOG5208L Docetaxel CDDP N ORR (%) 41 24* PFS (mo) * OS (mo) * G3-5 AE (%) * Statistically significant M. Socinski, Ann Oncol 2013 Takehito Shukuya, Lancet Oncology 2015
11 . Necitumumab is a second-generation human IgG1 anti-egfr monoclonal antibody First-line Stage IV Squamous-LC ECOG PS 0-2 R N=1093 Neci + Gem-Cis q3w (N=545) Necitumumab 800 mg D1, D8 Gemcitabine 1250 mg/m², D1, D8 Cisplatin 75 mg/m², D1 Maximum of 6 cycles Gem-Cis q3w (N=548) Gemcitabine 1250 mg/m², D1, D8 Cisplatin 75 mg/m², D1 CR PR SD PD Neci q3w 800 mg D1, D8 PD PD Randomization stratified by: ECOG PS (0-1 vs. 2) and geographic region (North America, Europe, and Australia; vs. South America, South Africa, and India; vs. Eastern Asia) Primary objective: OS Patient selection not based on EGFR protein expression Mandatory tissue collection from archived tumor Thatcher N. et al. Lancet Oncol 2015
12 Overall Survival (%) SQUIRE Primary Outcome: Overall Survival (ITT) 16% reduction risk of death, 1.6 month absolute improvement in OS Similar RR 31% vs 29% (p ns) GC+N N=545 Stratified HR (95% CI) 0.84 (0.74, 0.96) GC N=548 1yr OS Stratified p-value (log-rank) 0.01 Median, months (95% CI) 11.5 (10.4, 12.6) 9.9 (8.9, 11.1) 42.8% 47.7% 2yr OS Patients / events: Neci + Gem-Cis: 545 / 418 Gem-Cis: 548 / % 19.9% Time Since Randomization (Months) Thatcher N. et al. Lancet Oncol 2015
13 SQUIRE Exploratory Analysis: EGFR H-Score EMA approved only in EGFR expressing tumours, IHC (DAKO PharmDx): BUT only 5% tumors did not express EGFR (small sample size) OS H-Score >0 vs < 0: OS 11.7 vs 10 (HR 0.81) Thatcher et al. Lancet Oncol 2015; Paz-Ares Annals of Oncol 2016
14 Median OS (months) Second Line.very poor outcomes 9 < 9 months etaxel 0 Ifosfamide or vinorelbine Docetaxel Ifosfamide BSC or Pemetrexed Docetaxel Docetaxel BSC Pemetrexed Erlotinib Docetaxel Placebo Erlotinib Placebo vinorelbine TAX320 TAX317 TAX320 TAX317 JMEI BR.21 JMEI BR Fossella 2000; 2. Shepherd 2000; 3. Hanna 2004; 4. Shepherd 2005
15 * Ramucirumab, a fully human monoclonal antibody that specifically binds VEGFR2 Squamous: 157 (25%) Primary endpoint: OS Secondary: PFS, ORR, safety Analysis by histology NOT preplanned Squamous: 171 (27%) Garon EB et al. Lancet 2014;384:665-73
16 REVEL Primary Outcome: Overall Survival (ITT) 14% reduction risk of death, 1 month improvement in OS Garon EB et al. Lancet 2014
17 REVEL: Overall Survival by Histology * Subgroup analyses by histology in this study were not pre-planned Garon EB et al. Lancet 2014
18 REVEL: AEs of interests by histology Treatment Emergent Adverse Events Bleeding/ Haemorrhage* Epistaxis Gastrointestinal haemorrhage* Pulmonary haemorrhage* Haemoptysis Hypertension* Infusion-related reaction* Proteinuria Grade Nonsquamous Ramucirumab (N=465) Placebo (N=441) Ramucirumab (N=157) Squamous Placebo (N=170) Any 145 (31.2) 60 (13.6) 36 (22.9) 33 (19.4) 3/4/5 11 (2.4) 8 (1.8) 4 (2.5) 5 (2.9) Any 97 (20.9) 30 (6.8) 19 (12.1) 9 (5.3) 3/4/5 2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) Any 14 (3.0) 7 (1.6) 3 (1.9) 3 (1.8) 3/4/5 3 (0.6) 1 (0.2) 1 (0.6) 1 (0.6) Any 34 (7.3) 25 (5.7) 15 (9.6) 21 (12.4) 3/4/5 5 (1.1) 4 (0.9) 3 (1.9) 4 (2.4) Any 25 (5.4) 16 (3.6) 11 (7.0) 16 (9.4) 3/4/5 3 (0.6) 2 (0.5) 1 (0.6) 2 (1.2) Any 54 (11.6) 23 (5.2) 14 (8.9) 6 (3.5) 3/4/5 27 (5.8) 13 (2.9) 8 (5.1) 0 (0.0) Any 18 (3.9) 20 (4.5) 5 (3.2) 8 (4.7) 3/4/5 4 (0.9) 3 (0.7) 1 (0.6) 1 (0.6) Any 15 (3.2) 5 (1.1) 6 (3.8) 0 (0.0) 3/4/5 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) P value <0.05 between treatment groups, comparison based on Fisher s exact tests *Consolidated AE category comprising synonymous MedDRA preferred terms. Garon EB et al. Lancet 2014
19 SCC of the lung (Stage IIIB/IV) 1 Progressed after 4 cycles of a first-line platinum-doublet ECOG PS 0 1 Adequate organ function 1:1 N=795 Afatinib 40 mg * QD Erlotinib 150 mg QD Primary endpoint PFS by independent review Key secondary endpoint Overall survival Other secondary endpoints: ORR, DCR, tumor shrinkage, PRO, safety Stratified by east Asian vs non-east Asian *Dose escalation to 50 mg and dose reduction to 30 or 20 mg permitted Dose reduction to 100 or 50 mg permitted Tumor assessment at baseline, Weeks 8, 12, 16; every 8 weeks thereafter Soria, Lancet Oncol 2015
20 Estimated PFS probability Estimated OS probability LUX-Lung 8: Primary endpoint PFS 19% reduction risk of death, <1 month improvement in OS Similar RR 6% vs 3% (p ns) PFS OS Median, months (95% CI) Afatinib n= ( ) HR (95% CI) 0.81 ( ) p value Erlotinib n= ( ) Median, months (95% CI) Afatinib n= ( ) HR (95% CI) 0.81 ( ) p value Erlotinib n= ( ) % % 22.0% % Time of progression-free survival (months) Time of overall survival (months) Soria, Lancet Oncol 2015
21 LUX-Lung 8: Predictive analysis by OS Subgroup Aberration present (%) HR (95% CI) SVs CNAs Predefined families: y aberration LL8 LL8 subset* (n=238) EGFR TP53 LRP1B MLL2 CDKN2A FAT3 EGFR SOX2 KLHL6 PIK3CA MAP3K13 BCL6 FGF12 ERBB FGF No (94.1) Yes (5.9) No (12.2) Yes (87.8) No (60.5) Yes (39.5) No (67.2) Yes (32.8) No (71.4) Yes (28.6) No (72.3) Yes (27.7) No (93.7) Yes (6.3) No (56.3) Yes (43.7) No (59.7) Yes (40.3) No (63.0) Yes (37.0) No (67.2) Yes (32.8) No (68.9) Yes (31.1) No (71.4) Yes (28.6) No (71.0) Yes (29.0) No (41.2) Yes (58.8) 0.82 ( ) 0.73 ( ) 0.72 ( ) 1.04 ( ) 0.54 ( ) 0.74 ( ) 0.74 ( ) 0.73 ( ) 0.68 ( ) 0.83 ( ) 0.75 ( ) 0.68 ( ) 0.69 ( ) 0.75 ( ) 0.76 ( ) 0.42 ( ) 0.78 ( ) 0.70 ( ) 0.76 ( ) 0.72 ( ) 0.72 ( ) 0.78 ( ) 0.80 ( ) 0.66 ( ) 0.74 ( ) 0.79 ( ) 0.76 ( ) 0.77 ( ) 0.74 ( ) 0.70 ( ) 0.69 ( ) 0.76 ( ) Favors afatinib Favors erlotinib NONE Genetic Abnormality is predictive of benefit to afatinib treatment compared with erlotinib DO NOT not appear to be associated with longer PFS/OS J.C. Soria WCLC 2015
22 Squamous, male, heavy smoker I can t believe it! Jan 2016 June 2016 June 2017 Case report by N.Reguart, N. Vilariño
23 Squamous cell lung cancer has a very high rate of somatic mutations Squamous LC Lung adenoc 8.9 and SCC 8.1 mut/mb estimated from exome sequencing Lawrence et al. Nature 2014
24 TMB is higher in patients with smoking history Smoking history Govindan et al. Cell 2012
25 TME immuno type I common in lung tumors KRAS NSCLC MELANOMA TILs+ PD-L1+ Type I TILs- PD-L1- Type II Type IV PD-L1- TILs+ Type III PD-L1+ TILs- EGFR mutant NSCLC ALK rearranged NSCLC Ock et al. Clin Cancer Res 2016
26 PDL-1 TPS and histology PD-L1 TPS 1%_67% PD-L1 TPS 50%_ 28% * Data from KEYNOTE-001, -010, and -024 Aggarwal C, ASCO 2017
27 Randomize 1:1 CheckMate Study Design Stage IIIb/IV SQ NSCLC 1 prior platinum doublet-based chemotherapy ECOG PS 0 1 Nivolumab 3 mg/kg IV Q2W until PD or unacceptable toxicity n = 135 Primary Endpoint: OS Additional Endpoints: Investigator-assessed ORR Pre-treatment (archival or fresh) tumor samples required for PD-L1 analysis N = 272 Docetaxel 75 mg/m 2 IV Q3W until PD or unacceptable toxicity n = 137 Investigator-assessed PFS Correlation between PD-L1 expression and efficacy Safety Quality of life (LCSS) Patients stratified by region and prior paclitaxel use 100% SqCC One pre-planned interim analysis for OS At time of DBL (December 15, 2014), 199 deaths were reported (86% of deaths required for final analysis) The boundary for declaring superiority for OS at the pre-planned interim analysis was P <0.03 LCSS = Lung cancer symptom scale J. Brahmer, et al. N Engl J Med. 2015
28 OS (%) OS (%) CheckMate 017 in SCC: Primary endpoint OS Overall Survival 1 Updated OS 2 years follow-up mos mo, (95% CI) 18-mo OS rate = 13% CheckMate 017: Squamous Median OS Nivo = 9.2 months Nivolumab Docetaxel Time (months) Nivolumab (n = 135) 9.2 ( ) Docetaxel (n = 137) 6.0 ( ) # deaths HR = 0.59 (95% CI: ); P < mo OS rate = 28% yr OS=8% Time (months) 2-yr OS =23% Nivolumab Docetaxel 33 Based on August 2015 DBL. 1. J. Brahmer, et al. N Engl J Med. 2015; 2. Borghaei H et al. Poster presentation at ASCO 2016 Symbols refer to censored observations.
29 OS (%) CA Year Update: Phase 1 Nivolumab in Advanced NSCLC 100 Squamous (n = 54) 100 Non-squamous (n = 74) y OS, 41% 1 y OS, 42% y OS, 24% 3 y OS, 20% 5 y OS, 16% y OS, 24% 3 y OS, 17% 5 y OS, 15% No. at Risk Years Years Julie Brahmer, AACR 2017
30 CheckMate 017: Nivolumab benefit by PD-L1 Non-squamous NSCLC (CheckMate 057) 3 PREDICTIVE Squamous NSCLC (CheckMate 017) 1,2 NOT PREDICTIVE PD-L1 expression OS PFS 1% <1% 5% <5% 10% <10% NQ a 1% <1% 5% <5% 10% <10% NQ a Unstratified HR Interaction P-value < Unstratified HR Interaction P-value Nivolumab Docetaxel Nivolumab Docetaxel PD-L1-positive expression PD-L1-negative expression NQ 1. Brahmer J, et al. New Engl J Med. 2015;373: Spigel DR, et al. Presented at ASCO 2015, Abstract Paz-Ares L, et al. Presented at ASCO 2015, Abstract LBA109.
31 KEYNOTE 010- Study Design N = 1034 Coprimary Endpoints: OS and PFS 22% SqCC * No staification by histology Herbst R, Lancet 16
32 KEYNOTE-010: OS in ITT by PDL-1 expression OS, PD-L1 TPS 1% (total population) Treatment Arm Median (95% CI), mo Rate at 1 y HR a (95% CI) P Pembro 2 mg/kg 10.4 ( ) 43.2% 0.71 ( ) Pembro 10 mg/kg 12.7 ( ) 52.3% 0.61 ( ) < Docetaxel 8.5 ( ) 34.6% OS, PD-L1 TPS 50% stratum Treatment Arm Median (95% CI), mo HR a (95% CI) P Pembro 2 mg/kg 14.9 (10.4-NR) 0.54 ( ) Pembro 10 mg/kg 17.3 (11.8-NR) 0.50 ( ) < Docetaxel 8.2 ( ) O v e r a l l S u r v i v a l, % Time, months Pembro 2 vs 10 mg/kg: HR 1.17, 95% CI O v e r a l l S u r v i v a l, % Time, months Pembro 2 vs 10 mg/kg: HR 1.12, 95% CI Herbst R, Lancet 16
33 KEYNOTE-010: 3 years OS 29.5% 22.1% 12.3% Herbst RS, ASCO 2017
34 KEYNOTE-010: OS by Subgroups Subgroups Overall Sex Male New Histology Squamous Adenoc No. of Events/ No. of Patients 521/ / /399 Female Age <65 years 317/ years 204/429 ECOG performance status 0 149/ /678 PD-L1 tumor proportion score 50% 204/442 1% 49% 317/591 Tumor sample Archival EGFR status Mutant Wild type 266/ / / /708 46/86 447/875 Hazard Ratio (95% CI) ( ) 0.65 ( ) 0.69 ( ) 0.63 ( ) 0.76 ( ) 0.73 ( ) 0.63 ( ) 0.53 ( ) 0.76 ( ) 0.70 ( ) 0.64 ( ) 0.74 ( ) 0.63 ( ) 0.88 ( ) 0.66 ( ) Favors Pembrolizumab Favors Docetaxel Analysis cut-off date: September 30, Roy S. Herbst, ESMO ASIA 2015; Lancet 2015
35 KEYNOTE-010: Adjusted HR for OS (PD-L1 TPS 1%) Exploratory, post hoc, multivariate analyses Herbst RS, ASCO 2017
36 KEYNOTE-010: Subgroup analysis by PDL-1 Analysis of all 550 patients of antitumor activity of Pembrolizumab in advanced NSCLC enrolled in KEYNOTE-001 Hellmann WCLC 2015
37 OAK- Study Design Locally advanced or metastatic previously treated NSCLC Locally advanced/metastatic NSCLC Atezolizumab 1,200mg IV q3w Loss of clinical benefit Tumour specimen available (FFPE) R 1:1 No crossover 1 2 prior lines of chemo including 1 line of platinum chemo Docetaxel 75mg/m2 q3w PD All PD-L1 status allowed (N=850 enrolled) Stratification factors PD-L1 IC expression (0 vs 1 vs 2 vs 3) Histology (squamous vs nonsquamous) Primary endpoints (first 850 enrolled patients) OS in ITT population OS in patients with 1% PD-L1 expression (TC1/2/3 or IC1/2/3) Secondary endpoints ORR, PFS, and DoR Safety 26% SqCC Prior chemotherapy regimens (1 vs 2) Rittemeyer Lancet 17
38 Overall Survival, % OAK study: OS ITT (N = 850) Atezolizumab Docetaxel 12-mo OS 55% 41% Median 13.8 vs 9.6 mo HR, 0.73 a (95% CI, 0.62, 0.87) P =.0003 Minimum follow-up = 19 months 18-mo OS 40% 27% Months a Stratified HR Rittemeyer Lancet 17
39 Overall survival (%) Overall survival (%) OAK: OS by histology non-squamous ITT (n=628) Atezolizumab Docetaxel Minimum follow-up 19 months Landmark OS 12 month 59% 46% Landmark OS 18 month 44% 31% Median OS, mo (95% CI) 15.6 (13.3, 17.6) 11.2 (9.3, 12.6) HR (95% CI) 0.73 (0.60, 0.89); P= squamous ITT (n=222) Atezolizumab Docetaxel Minimum follow-up 19 months Landmark OS 12 month 42% 29% Landmark OS 18 month 30% 16% Median OS, mo (95% CI) 8.9 (7.4, 12.8) 7.7 (6.3, 8.9) HR (95% CI) 0.73 (0.54, 0.98); P= Atezolizumab Docetaxel Atezolizumab Docetaxel Median 11.2 mo (95% CI, 9.3, 12.6) Median 15.6 mo (95% CI, 13.3, 17.6) Median 7.7 mo (95% CI, 6.3, 8.9) Median 8.9 mo (95% CI, 7.4, 12.8) Time (months) Time (months) Rittmeyer, et al. Lancet 2016; Barlesi, et al. ESMO 2016 (abstr LBA44); Roche data on file
40 OAK: OS HR by histology and PD-L1 Subgroup Non-squamous TC3 or IC3 TC2/3 or IC2/3 TC1/2/3 or IC1/2/3 TC0 and IC0 All non-squamous n (%) 96 (15%) 188 (30%) 333 (53%) 290 (46%) 628 (100%) HR Median OS, mo Atezolizumab Docetaxel Squamous TC3 or IC3 TC2/3 or IC2/3 TC1/2/3 or IC1/2/3 TC0 and IC0 All squamous 41 (18%) 77 (35%) 130 (59%) 89 (40%) 222 (100%) ITT In favour of atezolizumab Hazard Ratio In favour of docetaxel Gadgeel, et al. WCLC 2016 (abstr PL04a.02)
41 KEYNOTE-024: First Line Pembrolizumab A Phase III, randomized, open-label study of pembrolizumab vs platinum-doublet chemotherapy as firstline therapy in patients with advanced or metastatic NSCLC that expresses PD-L1 in 50% of tumor cells Pembrolizumab 200 mg Q3W Key Inclusion Criteria (2 years) Advanced, previously untreated NSCLC PD-L1+ tumor expression 50% No EGFR sensitizing mutation or ALK translocation ECOG PS 1 R 1:1 Optional crossover after disease progression Investigator choice of platinum-based chemotherapy 50% N=305 For 4 6 cycles Primary endpoint: PFS (RECIST v1.1 per blinded, independent central review) Secondary endpoints: ORR, OS, safety, and tolerability Exploratory endpoint: DOR 19% SqCC Reck M et al. N Engl J Med. 2016
42 PFS, % OS, % KEYNOTE-024: PFS and OS (PD-L1 50%) Events, n Median, mo HR (95% CI) P Events, n Median, mo HR (95% CI) P Pembro Chemo ( ) <0.001 Pembro 44 NR 0.60 Chemo 64 NR ( ) % 72% 70% 54% % 50% 48% 15% Time (months) Time (months) Reck M et al. N Engl J Med. 2016
43 KEYNOTE-024: PFS in Subgroups Reck M et al. N Engl J Med. 2016
44 New strategies for SqCC-NSCLC Trial Eligibility N /EP Bio-marker Study Arms Roche IMpower-131 Stage IIIB/IV Squamous, MSD KN-407 Stage IV, Squamous Roche IMpower Stage IIIB/IV, Chemonaïve SCC/non-SCC AZ MYSTIC Stage IIIB/IV SCC/non-SCC AZ NEPTUNE Stage IIIB/IV SCC/non-SCC BMS CM-227 Stage IIIB/IV, SCC/non-SCC 1200 PFS 560 PFS/OS 570 PFS/OS 675 PFS 800 OS 1980 PFS/OS All corners 1. Atezo+ Carbo/taxol_ Atezo man 2. Atezo+ Carbo/ Nab-paclitaxel_ Atezo man 3. Carbo/ Nab-paclitaxel All corners 1. Pembro + Carboplatin/ Nabpaclitaxel/taxol 2. Carboplatin/ Nab-paclitaxel/taxol PD-L1 expression (TC or IC 1% [TC1/2/3 or IC1/2/3]) Collected, not defined for eligibility Collected, not defined for eligibility 1. Atezo 2. Chemo 1. Durva + Treme 2. Durva 3. Chemo 1. Durva + Treme 2. Chemo PDL1 positive 1. Nivo 2. Nivo + Ipi 3. Nivo + Chemo 4. Chemo NCT Phase I Safety 1. Pembro + Necitumumab 4 8
45 ESMO Guidelines for Advanced Stage IV SCC Silvia Novello, ESMO Guidelines, Annals of Oncol 2016
46 ESMO Guidelines for Advanced Stage IV SCC Silvia Novello, ESMO Guidelines, Annals of Oncol 2016
47
48 * Nectimumumab and afatinib not recommended in updated NCCN
49 New Algorism for SqCC Lung Cancer Treatment OS HR 0.35 OS HR 0.35 Necitumumab??? OS HR 0.84 OS HR 0.59, 0.74, 0.73 OS HR 0.59, 0.74, 0.73 HR 0.88 HR 0.88 Afatinib??? OS HR 0.81 Yi-Chen Zhang, ESMO open 2016
50 THANK YOU!!!
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationRecent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationAlgoritmo de tratamiento del CNMP escamoso. Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla
Algoritmo de tratamiento del CNMP escamoso Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla Agenda CNMP escamoso vs no escamoso: diferencias? Opciones de tratamiento 1L Opciones de tratamiento
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationSquamous Cell Carcinoma: What are the Standards and Potential Pathways in Development
Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development Dr. Luis Corrales- Rodríguez Oncología Médica Centro de Investigación y Manejo del Cáncer (CIMCA) Servicio de Oncología-
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationHacia una mayor individualización clínica en el CPNM. J.M. Sánchez Torres H.U. Princesa, Madrid
Hacia una mayor individualización clínica en el CPNM J.M. Sánchez Torres H.U. Princesa, Madrid Lung cancer histologic subtypes NSCLC (80-85%) SCLC (15-20%) Squamous carcinoma (25 30%) Non-squamous carcinoma
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationSecond-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial
Second-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial lenwood oss, Manuel Cobo, Shun Lu, Konstantinos Syrigos,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationIMMUNE CHECKPOINT BLOCKADE FOR NSCLC. Marina Chiara Garassino
IMMUNE CHECKPOINT BLOCKADE FOR NSCLC Marina Chiara Garassino Cells of the Immune System Innate immune system: Involving proteins (chemokines and cytokines) and cells, is considered to be the first line
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationCáncer de pulmón no microcítico
DEFINIENDO LA SECUENCIA O PTIMA DE TRATAMIENTO EN CA NCER AVANZADO Cáncer de pulmón no microcítico Enriqueta Felip Hospital Vall d Hebron, Barcelona Molecular events in NSCLC Adenocarcinoma EGFR-resistance
More informationOptimizing Outcomes in Advanced Non-Small Cell Lung Cancer: Integrating Novel Personalized Therapy into the Treatment Paradigm. Joel W.
Optimizing Outcomes in Advanced Non-Small Cell Lung Cancer: Integrating Novel Personalized Therapy into the Treatment Paradigm Joel W. Neal, MD, PhD Assistant Professor of Medicine/Oncology Stanford University/Stanford
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationesmo.org ESMO IMMUNO-ONCOLOGY CONGRESS 2017
ESMO IMMUNO-ONCOLOGY CONGRESS 2017 Primary PFS and safety analyses of a randomised Phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic
More informationSummary THORACIC MALIGNANCIES NSCLC, Metastatic... 4
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 3 THORACIC MALIGNANCIES NSCLC, Metastatic... 4 PD-1 inhibition shows promise as first-line treatment in high PD-L1
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More information